I. COMMENCED TRADING IN JUNE

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out
(M)%

Lead, Other Underwriters

Gross (M)

Post-
Offering
Market
Cap (M)@


INITIAL OFFERINGS

BioDelivery Sciences Inc. (BDSIU)1

11/2002

6/27

2U

$5.25

7

Kashner Davidson Securities; Roan Meyers Assoc.; Investors Capital; Sterling Financial Investment; Schneider Securities

$10.5

N/A

YM BioSciences Inc. (Canada; AIM:YMB; TSE:YM_PB)2

4/24/02

6/12/02

3.75S

C$4

16.75

Canaccord Capital

N/A

C$67 (US$43.8)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

% This column reflects the shares outstanding following the offering, when disclosed.

@ Market capitalization calculated is based on the offering price.

AIM = Alternative Investment Market on the London Stock Exchange; TSE = Toronto Stock Exchange

1. BioDelivery's underwriters have an overallotment option on 300,000 units. Each unit consists of one share and once Class A warrant, exercisable to purchase one share.

2. YM BioSciences went public on the London and Toronto stock exchanges, issuing stock to institutional and other investors at C$4 each. The amount raised, C$15M (US$9.74M), is accounted for in the "Other Financings Of Public Biotechnology Companies" chart in this issue.

Total: $10.5M

Number of IPOs in June: 1

Average value of June IPOs: $10.5M

Number of IPOs in 2002: 4

Total raised in IPOs in 2002: $464.3M*

Average value of IPOs in 2002: $116.08M*

* Figures include an overallotment option exercised in January as part of a 2001 IPO.

Figures do not include an IPO conducted in June by YM BioSciences Inc. because the shares were privately placed.

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date Comm.

Shares/
Units (M)

Price

Shares
Out
(M)%

Lead, Other Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)@


BioTransplant Inc. (BTRN)3

12/11/01

6/12

4S

$2.50

25.3

N/A

$10

$63.25

ProMetic Life Sciences Inc. (Canada; TSE:PLI)4

5/30/02

6/17

9.34S

C$2.70

N/A

Dundee Securities Corp.; National Bank Financial; Scotia Capital; Desjardins Securities

C$25.2 (US$16.3)

N/A

The Medicines
Company Inc.
(MDCO)5

4/23/02

6/21

4S

$8.20

39

Bear, Stearns & Co.

$32.8

$319.8


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

% This column reflects the shares outstanding following the offering, when disclosed.

@ Market capitalization calculated is based on the offering price.

TSE = Toronto Stock Exchange

3. BioTransplant raised $10M in a public offering of 4M shares, pursuant to a shelf registration filed in December.

4. ProMetic Life Sciences raised $16.3M in a public offering. It also raised $650,000 in a concurrent private placement.

5. The Medicines Company raised $32.8M in a public offering.

Total: $59.1M

Number of follow-on offerings in June: 3

Average value of June follow-ons: $19.7M

Number of follow-on offerings in 2002: 15

Total raised in follow-ons in 2002: $529.93M

Average value of follow-ons in 2002: $35.33M

II. FILED AND PENDING

Company (Symbol/
Proposed Symbol)#*

Date Filed

Shares/
Units (M)

Price Range

Shares
Out
(M)%

Lead,
Other
Underwriters

Value (M)


INITIAL OFFERINGS

Aderis Pharmaceuticals Inc. (ADPX)1

1/11/02

5.5S

$9-11

N/A

UBS Warburg (co-lead); CIBC World Markets (co-lead); RBC Capital Markets; Gerard Klauer Mattison

$55

Corcept Therapeutics Inc. (CORT)2

12/21/01

4S

$14-16

23.9

U.S. Bancorp Piper Jaffray (co-lead); CIBC World Markets (co-lead); Thomas Weisel Partners

$60

DiaDexus Inc. (DDXS)3

11/20/00

7S

$12-14

31.1

Lehman Brothers; CIBC World Markets; Robertson Stephens; Fidelity Capital Markets

$91

Innovative Drug Delivery Systems Inc. (IDDS)4

1/2/02

5.6S

$8-10

20.65

Thomas Weisel Partners; Wells Fargo Securities; Jefferies & Co.

$50.4

MitoKor Inc. (MITO)5

3/8/02

N/A

N/A

N/A

RBC Capital Markets; Lazard Freres; Legg Mason Wood Walker; Gerard Klauer Mattison

$60

Novirio Pharmaceuticals Ltd. (IDIX)6

4/12/02

N/A

N/A

N/A

Goldman Sachs (co-lead); Banc of America Securities (co-lead); JP Morgan Securities; U.S. Bancorp Piper Jaffray

$115

Protarga Inc. (PRTG)7

12/12/01

N/A

N/A

N/A

UBS Warburg (co-lead); U.S. Bancorp Piper Jaffray (co-lead)

$75

ViaCell Inc. (VIAC)8

1/30/02

N/A

N/A

N/A

UBS Warburg; Banc of America Securities; U.S. Bancorp Piper Jaffray

$115

FOLLOW-ON OFFERINGS

Advanced Tissue Sciences Inc. (ATIS)9

6/12/02

10S

$1.07

N/A

N/A

$10.7

Antigenics Inc.
(AGEN)10

6/13/02

N/A

N/A

33.1

N/A

$100

Ariad Pharmaceuticals Inc. (ARIA)11

1/9/02

3S

$5.28

35.4

N/A

$15.84

Biomira Inc. (Canada; BIOM; TSE:BRA)12

5/2/02

N/A

N/A

N/A

N/A

C$150
(US$97.84)

Biosante Pharmaceuticals Inc. (OTC BB:BTPH)13

5/6/02

N/A

N/A

N/A

Self-underwritten

$10

Celgene Corp.
(CELG)14

12/21/01

N/A

N/A

75.6

N/A

$500

Cell Pathways Inc. (CLPA)15

2/7/01

N/A

N/A

N/A

N/A

$25

Cepheid Inc.
(CPHD)16

12/21/01

N/A

N/A

26.56

N/A

$35

Cerus Corp.
(CERS)17

8/13/01

N/A

N/A

15.7

N/A

$300

CollaGenex Pharmaceuticals Inc. (CGPI)18

10/26/01

0.965S

$8.01

N/A

Kingsbridge Capital; Prentice Securities

$7.7

Cytogen Corp.
(CYTO)19

10/26/01

10S

$2.50

79.8

N/A

$25

Dyax Corp.
(DYAX)20

4/25/02

5S

$3.66

19.6

N/A

$18.3

EntreMed Inc.
(ENMD)21

5/10/02

N/A

N/A

N/A

N/A

$50

Exelixis Inc.
(EXEL)22

7/30/01

N/A

N/A

49.2

N/A

$150

Genaera Corp.
(GENR)23

11/21/01

N/A

N/A

38.9

N/A

$50

Genaissance Pharmaceuticals Inc. (GNSC)24

10/18/01

N/A

N/A

22.8

N/A

$35

Geron Corp.
(GERN)25

1/30/02

N/A

N/A

N/A

N/A

$150

Hollis-Eden Pharmaceuticals Inc. (HEPH)26

2/26/02

3S

$8.71

N/A

N/A

$26.13

InSite Vision Inc. (AMEX:ISV)27

2/2/01

N/A

N/A

N/A

Ladenburg Thalmann (placement agent)

$40

Myriad Genetics Inc. (MYGN)28

11/9/01

N/A

N/A

N/A

N/A

$250

NeoTherapeutics Inc. (NEOT)29

1/3/01

N/A

N/A

26.9

N/A

$50

Northwest Biotherapeutics Inc. (NWBT)30

6/4/02

11S

$3.77

17

C.E. Unterberg, Towbin

$41.5

NPS Pharmaceuticals Inc. (NPSP)31

1/7/02

N/A

N/A

N/A

N/A

$250

Pharmos Corp.
(PARS)32

2/4/02

N/A

N/A

56.6

N/A

$25

SciClone Pharmaceuticals Inc. (SCLN)33

11/6/01

N/A

N/A

N/A

N/A

$20

StemCells Inc.
(STEM)34

3/8/02

15S

N/A

N/A

N/A

$37.8

Targeted Genetics
Corp.
(TGEN)35

12/13/01

8.84S

$2.57

N/A

N/A

$22.72

Telik Inc. (TELK)36

6/3/02

N/A

N/A

27.8

N/A

$100

Tularik Inc. (TLRK)37

8/14/01

N/A

N/A

49.2

N/A

$250

III. WITHDRAWN AND POSTPONED

Company (Symbol/
Proposed Symbol)#*

Date Filed/ Date Pulled

Shares/
Units (M)

Price Range

Shares
Out
(M)

Lead,
Other
Underwriters

Value (M)


INITIAL OFFERINGS

Royalty Pharma AG (Switzerland)38

N/A 6/26**

4.1S

CHF40 (US$26.74)

N/A

UBS Warburg

CHF164 (US$109.63)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

** Denotes the date the item ran in BioWorld International.

% This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange

1. Aderis set in April the number of shares and the price range of its IPO. It amended the price range in May. The value, $55M, is based on the sale of 5.5M shares at $10 each, the midpoint of the expected price range. The underwriters have an overallotment option on 825,000 shares.

2. Corcept's offering is for 4.5M shares, 4M sold by the company and 500,000 sold by a selling stockholder. The value of Corcept's offering, $60M, is based on the sale of 4M shares at $15 each, the midpoint of the expected price range.

3. DiaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option on 1.05M shares.

4. Innovative Drug set the number of shares to be sold and the price range in March. The value, $50.4M, is based on the sale of 5.6M shares at $9 each, the midpoint of the expected price range. The underwriters have an overallotment option on 840,000 shares.

5. MitoKor filed for an IPO to raise $60M.

6. Novirio filed for an IPO to raise $115M.

7. Protarga filed for an IPO with hopes of raising $75M. It did not disclose the number of shares to be offered or the expected price range.

8. ViaCell filed for a $115M IPO. No further details were disclosed.

9. Advanced Tissue filed a shelf registration statement with the SEC to issue up to 10M shares of its common stock. The value, $10.7M, is based on the June 12 closing stock price of $1.07.

10. Antigenics filed a shelf registration statement covering the issuance of common and preferred stock, as well as secured and unsecured debt securities, up to $60M. It also had a previous registration with $40M in securities remaining.

11. Ariad filed a shelf registration statement to sell up to 3M shares. At the Jan. 8 closing stock price, it would raise $15.84M.

12. Biomira filed for a $150M shelf prospectus in Canada.

13. BioSante filed for a proposed self-underwritten offering of up to $10M in shares of common stock.

14. Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M.

15. Cell Pathways filed a shelf registration statement for the sale of $25M in common stock.

16. Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants.

17. Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

18. The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01. CollaGenex privately placed 119,335 shares in May, raising $1M. It placed 32,187 shares in June, raising $266,667.

19. Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration statement. It privately placed 3M shares in January, and another 4.17M shares in June.

20. Dyax filed a shelf registration statement to sell up to 5M shares. The value, $18.3M, is based on the April 24 closing stock price, $3.66.

21. EntreMed filed a $50M shelf registration statement, allowing it to offer securities from time to time in the form of common stock, preferred stock or warrants to purchase securities.

22. Exelixis filed a shelf registration statement to sell up to $150M in common stock.

23. Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock. It privately placed $16.5M in shares in April.

24. Genaissance filed a shelf registration statement to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M.

25. Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants.

26. Hollis-Eden filed a shelf registration statement to sell up to 3M shares and warrants from time to time. The value is based on the proposed maximum offering price.

27. InSite filed a shelf registration statement in February 2001 to sell $40M in stock.

28. Myriad filed a shelf registration statement for the sale of up to $250M of various types of securities.

29. NeoTherapeutics filed a shelf registration statement covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. In May 2001, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. In November, it placed 950,000 shares, raising $3.8M. In December, it placed 0.77M shares, raising $2.95M. In March 2002, it raised $8.05M in a private placement. In June, it raised $1.66M in a private placement.

30. Northwest expects to offer 11M shares as part of a lock-up agreement with the underwriter from the company's December initial public offering. The value, $41.5M, is based on the June 3 closing stock price of $3.77.

31. NPS filed a shelf registration statement to offer and sell up to $250M of common stock, preferred stock and debt securities.

32. Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants.

33. SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering. SciClone privately placed $10.62M in shares in June.

34. StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed.

35. Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22 closing stock price of $2.57.

36. Telik filed a shelf registration statement to sell $100M in common stock, preferred stock, debt securities and warrants.

37. Tularik filed to sell up to $250M in common stock and debt securities.

38. Royalty Pharma canceled its initial public offering on the Swiss Stock Exchange in Zurich, citing bad market conditions.

No Comments